New Center

• Generation of Functional Monoclonal Antibodies by Single B Cell Cloning. Learn more>>

• FucoFree - afucosylated antibody with enhanced antibody-dependent cellular cytotoxicity. Learn more>>

• Advanced Tools for Virology Research. Learn more>>

• Tools for Immune Checkpoint Therapeutic Antibodies Research. Learn more>>

• Immunologic Testing for COVID-19. Learn more>>

• Application of Molecular Interaction Technology in the Research SPR and BLI. Learn more>>

• Recombinant Protein Expression, Challenges and Solutions. Learn more>>

• The Production And Application of Antibody Fragments. Learn more>>

• Tools for COVID-19 Research. Learn more>>

• Sino Biological Wins Two of 2021 CiteAb Annual Awards. Learn more>>

• January, 15, 2021. Sino Biological Adds Further Support for Reproducibility. Learn more>>

• January, 4, 2021. Sino Biological, Inc has been Selected as the 2020 Bioz Stars Award Winner in the COVID-19 Category. Learn more>>

• One-hour, microfluidic SARS-CoV-2 antibody immunoassay using Sino Biological reagents and Gyrolab® immunoassay platform Learn more>>

• Sino Biological Deposits SARS-CoV-2 Antibody and Antigens to BEI Resources. Learn more>>

• May 9, 2020. Sino Biological sponsored a free webinar on SARS-CoV-2 (Covid-19) vaccine development. Learn more>>

• April 30, 2020. GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-CoV-2 (COVID-19) Vaccine Development. Learn more>>

• April 16, 2020. Sino Biological Partners with Nanommune Inc. to Develop and Market a Novel Coronavirus Multiplex Serological Assay, Sinommune^TM. Learn more>>

• March 31, 2020. Sino Biological Inc. will launch the world largest recombinant viral antigen collection, ProVir^TM, on April 1st. Learn more>>

• March 19, 2020. Sino Biological Inc. has received support from the Bill & Melinda Gates foundation for the colloidal gold and ELISA based diagnosis of COVID-19. Learn more>>

• January 22, 2020. Sino Biological is the first company worldwide to offer recombinant proteins of SARS-CoV-2. Learn more>>

• May 18, 2020. Researchers at Humabs Biomed SA and the University of Washington recently published a Nature article demonstrating the cross-neutralization of SARS-CoV-2 (Covid-19) using a monoclonal antibody recognizing three SARS RBD spike protein antigens (cat. numbers 40592-V31H, 40592-V05H and 40150-V08B1) developed at Sino Biological. Click this link to read the article!

• May 13, 2020. Researchers at Peking University and Beijing Youan Hospital jointly find a potent neutralizing antibodies against SARS-CoV-2 from convalescent patients identified by high-throughput single-cell sequencing of B cells. Sino Biological provide the the technical assistance on mAbs expression and characterization. Click this link to read the article!